HealthLynked (HLYK) AI Stock Analysis

• Market Cap: $8.21M
• Dividend Yield: N/A
• Average Volume (3M): 225.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: -44.16%
• EPS Growth: 5.53%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 65
• Industry: Medical - Care Facilities
• EPS (TTM): -0.02
• Shares Outstanding: 281,947,660
• 10 Day Avg. Volume: 130,856
• 30 Day Avg. Volume: 225,921
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.92
• Price to Cash Flow (P/CF): -2.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

HealthLynked's overall stock score is significantly impacted by its poor financial performance, characterized by declining revenues, substantial net losses, and negative equity. The technical indicators suggest a bearish trend with weak momentum, and the valuation metrics highlight ongoing losses and lack of investor income. The absence of positive developments in earnings calls or corporate events further weighs on the stock's attractiveness.

HealthLynked Business Overview & Revenue Model

Company Description

HealthLynked (HLYK) is a healthcare technology company focused on improving the coordination of medical care through its proprietary cloud-based platform. The company operates within the healthcare and technology sectors, offering a range of services including patient scheduling, medical record storage, and healthcare analytics. Its core product is the HealthLynked Network, a system designed to connect patients with healthcare providers to enhance communication and improve outcomes.

How the Company Makes Money

HealthLynked generates revenue primarily through its subscription-based model, where patients and healthcare providers pay monthly or annual fees to access the HealthLynked Network. Additionally, the company earns income from its healthcare analytics services, which are offered to providers seeking to leverage data for improved patient care and operational efficiency. Key partnerships with healthcare providers and institutions further contribute to its earnings, as these collaborations help expand its user base and enhance the platform's capabilities.

HealthLynked Financial Statement Overview

Summary

HealthLynked is facing severe financial challenges characterized by declining revenues, persistent losses, high leverage, and negative equity. The income statement, balance sheet, and cash flow scores indicate a need for strategic restructuring and improved operational efficiency.

Income Statement

HealthLynked's income statement shows significant challenges, with declining revenues and persistent losses. The TTM (Trailing-Twelve-Months) gross profit margin is low at around 13.3%, and the net profit margin is deeply negative. Revenue has decreased considerably from previous periods, indicating a need for strategic adjustments to improve financial performance.

Balance Sheet

The balance sheet reveals a concerning financial position. The company has negative stockholders' equity in the most recent period, indicating high leverage and financial instability. The debt-to-equity ratio is not meaningful due to negative equity, and this poses significant risks to long-term viability.

Cash Flow

Cash flow analysis indicates severe liquidity constraints, with negative operating and free cash flows. The company is reliant on financing activities to cover cash shortfalls. The free cash flow growth rate is negative, reflecting ongoing cash burn without signs of improvement.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
3.32M	5.72M	5.86M	9.20M	6.13M	4.02M
	Gross Profit
442.44K	2.35M	5.40M	6.18M	4.97M	-220.21K
	EBIT
-5.04M	-4.15M	-5.91M	-5.04M	-3.07M	3.95M
	EBITDA
-4.87M	-2.75M	-7.05M	-9.85M	-4.73M	-3.82M
	Net Income Common Stockholders
-6.19M	-1.01M	-8.82M	-10.41M	-6.15M	-14.32M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
29.78K	247.22K	61.89K	3.29M	162.18K	110.44K
	Total Assets
492.88K	4.28M	4.58M	10.69M	8.03M	2.55M
	Total Debt
324.94K	1.97M	1.28M	978.19K	2.89M	2.57M
	Net Debt
295.17K	1.73M	1.22M	-2.31M	2.73M	2.46M
	Total Liabilities
789.16K	3.48M	4.27M	3.49M	6.68M	5.39M
	Stockholders Equity
-296.27K	804.73K	314.45K	7.20M	1.35M	-2.84M
Cash Flow		Free Cash Flow
-3.94M	-4.15M	-4.39M	-3.79M	-2.14M	-2.37M
	Operating Cash Flow
-3.94M	-4.14M	-4.36M	-3.77M	-2.12M	-2.36M
	Investing Cash Flow
1.18M	3.51M	-544.75K	-341.36K	1.81M	-475.06K
	Financing Cash Flow
2.72M	824.09K	1.68M	7.24M	356.80K	2.81M

HealthLynked Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLYK, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.05, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 39.76 is Neutral, neither overbought nor oversold. The STOCH value of 39.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HLYK.

HealthLynked Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
POAI	51 Neutral	$10.96M	―	-292.08%	―	-23.75%	34.05%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
BMRA	45 Neutral	$10.40M	―	-77.33%	―	1.39%	13.89%
PRPO	42 Neutral	$9.43M	―	-32.35%	―	21.95%	39.43%
HLYK	35 Underperform	$8.21M	―	320.09%	―	-44.16%	5.53%
MSPR	31 Underperform	$8.99M	―	-33.24%	―	24.77%	13.53%
TSBX	29 Underperform	$9.48M	―	-108.87%	―	-100.00%	-27.44%

HealthLynked Corporate Events

HealthLynked Appoints New CFO Amid Leadership Changes

HealthLynked Corp. announced the appointment of Jeremy Daniel as its new Chief Financial Officer, effective January 15, 2025, following the resignation of David Rosal. Jeremy Daniel, with over two decades of experience in financial management and strategic planning across diverse industries, is expected to strengthen HealthLynked’s executive leadership and drive the company’s financial strategy, growth, and operational efficiency.